It was a pleasure to be onsite at Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa last week, a leading event gathering senior decision-makers to discuss commercialization hurdles facing the cell and gene therapy sector today. It was great to speak with so many key leaders on topics from clinical trial design to alternative payment models, and we look forward to continuing these important conversations across the industry. Please reach out to our team directly if you are interested in discussing. #CGMesa24
Great Point Partners’ Post
More Relevant Posts
-
How do you choose the right CDMO for gene engineering? David Hermanson, Director of Cell and Gene Therapy Applications at Bio-Techne, participated in a dynamic panel, hosted by ISCT, to discuss this topic. Together with industry experts Jeff Liter, Luminary Therapeutics and Farzin Farzeneh, Virocell, they explored the critical factors to consider when sourcing a CDMO. Discover key insights from their conversation in our latest blog post, where we also explore the use of viral and non-viral methods. Read more now: bit.ly/4cYQuX8
-
-
Don’t miss your opportunity to catch Coriolis Pharma's "Paving the Way to a Successful AAV Product" webinar, November 20th, 2024, at 4pm CET / 10am ET. Learn from leading experts Prof. Dr. Susumu Uchiyama and Dr. Melanie Schwerdtfeger as they tackle the analytical and manufacturing challenges of AAVs in gene therapy. Key takeaways include: - Analytical methods for AAV characterization - Monitoring quality attributes during manufacturing - Strategies for measuring AAV infectivity and optimizing production Register now to secure your spot: https://lnkd.in/ebAMJRHc
-
-
See you in Rome next week at #ESGCT2024 ! 🍕 ❓ Are you encountering challenges with your Cell & Gene Therapy clinical trials ? Or perhaps you're planning one and would like to better understand the challenges and how to navigate them? Let’s connect and discuss how we can help you succeed! 🤝 📩 Feel free to drop me a message, and we can schedule a time to chat. Looking forward to fruitful conversations and insights ! #Biotech #Pharma #CellTherapy #GeneTherapy
-
-
Engaging discussion on the challenges, emerging trends, and key value drivers shaping the Cell & Gene Therapy (C>) space, as well as the potential growth opportunities in Europe at Advanced Therapies Europe 2024. At Invivo Partners, we’re confident that the C> field will continue to advance, with promising expansions into new indications, the exploration of novel cell types, and the development of cutting-edge technologies to tackle the challenges ahead. #ATE24
-
-
Discover how decentralized manufacturing is reshaping the landscape of cell and gene therapy development in this blog capturing insights from our Bridging the Gap webinar series. Gain valuable insights from experts like Dorothea Ledergerber, PhD, Chief Technical Officer at Tigen Pharma, and Patrick Hanley, PhD, Director of the Cellular Therapy Program at Children’s National Hospital. Read the full blog and register for future webinars here: https://hubs.ly/Q02xHWy70 #CellTherapy #GeneTherapy #Innovation #WebinarSeries
-
-
Meet the Sannova team at The American Society of Gene & Cell Therapy (ASGCT) annual meeting, booth # 2048. Conference highlights: ✅Cutting-edge Research ✅Networking Opportunities ✅Professional Development Discover new tools, technologies, and resources essential for advancing your work. Stay up-to-date with industry trends, regulations, and potential future directions in cell and gene therapy. Going to ASGCT2024? Introduce yourself in the comments. #biotech, #immunotherapy, #ASGCT2024 #genetherapy #celltherapy
-
-
Consider this 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝘁𝗼 𝗴𝗮𝗶𝗻 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗮𝗻𝗱 𝗰𝗼𝗻𝗻𝗲𝗰𝘁𝗶𝗼𝗻𝘀 that will drive the 𝘀𝘂𝗰𝗰𝗲𝘀𝘀𝗳𝘂𝗹 𝗹𝗮𝘂𝗻𝗰𝗵 𝗼𝗳 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗰𝗲𝗹𝗹 𝗮𝗻𝗱 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝘀. My presentation will focus on setting apart your therapy for payers through science. My panel will discuss strategies for cross-functional collaboration. 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗴𝗲𝗻𝗱𝗮 𝗵𝗲𝗿𝗲 – https://ter.li/lhvjuu
-
-
come to discuss the affinity convective chromatography for cgt therapy regear chromatographt
Extpure will attend the 'ESGCT 31st Annual Congress 2024', held at the LA NUVOLA conference centre in Rome, Italy, from 22 to 25 October 2024. This will be the first overseas promotion of the Extpure Affinity Convective Chromatography (ACC) . At the event, Extpure will present new progress of purification technology in Cell and Gene Therapy field. Come to talk with us at booth B09.
-
-
✔️ Looks like it was a great week in Liverpool from the feedback - Lots of change since I last attended the BioIndustry Association (BIA) BioprocessUK at the Manchester Midland, just before I moved to India. ⏳ The big subjects then were protein therapeutic processing and the importance of yield, stability, and aggregation. The focus has shifted since then to Gene & Cell Therapies, as you might expect - how to process and manufacture these innovative medicines more efficiently to maximise patient-benefit. 🧬 Whether it be mAbs or Gene Therapies, or any of the other cutting-edge modalities being developed to improve health, Malvern Panalytical Pharmaceuticals has the biophysical tech and knowledge to de-risk and speed up your development processes. For more, please see here: https://lnkd.in/gj57ZxMi #CGT #BioprocessUK #mAb #Biologics
This week at the BioIndustry Association (BIA)'s bioProcessUK 2024 event, Stephen Ward, Chief Technology Officer at the CGT Catapult, joined an panel discussion on #sustainable manufacturing. The panel provided expert insights into the future of cell and gene therapy and the need for manufacturing to align with commercial goals. Learn more about upcoming events we are involved in: https://ow.ly/6KH950Ub5Sf #bioProcessUK #BIA #CellandGene
-
-
To navigate the intricate challenges that define #CGT distribution, a forward-thinking approach is foundational to achieving commercial success. In an interview with Pharm Exec, Cencora’s Melissa Lattanzi, Vice President, Emerging Therapies, delves into crucial considerations that cell and gene therapy (CGT) developers must address to shape an effective distribution strategy ⬇️ https://ow.ly/GuyI50SEvb1
-